News
Fareva and ApiJect sign a licensing agreement to create a France-based 500M unit annual capacity for single-dose prefilled vaccine injections
Fareva and ApiJect Systems, Corp. announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish...
Press Releases
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Pfizer Inc. and BioNTech SE announced that the U.S. FDA has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech...
News
Aerogen and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO have announced a development and commercial supply partnership for the inhaled delivery of...
Drug Research
FDA clears AstraZeneca’s Covid antibody treatment for immunocompromised
The FDA authorized the first injectable monoclonal antibody cocktail for long-term prevention of Covid-19 among people with weakened immune systems before they have been...
News
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced that the...
Drug Research
Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Eli Lilly and Company and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel...
Drug Research
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Roche announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read